< 1 minute read
Dec. 10, 2021

Eliapixant: A P2X3 Purinoreceptor Antagonist


oral P2X3 ion channel antagonist Ph. II, multiple settings (50-750 mg BID) from literature P2X3 antagonists Scientific Reports Bayer AG, Berlin, DE

Drug Hunter Team

The Bayer P2X3 purinoreceptor antagonist, eliapixant (BAY1817080), is intended to treat various disorders associated with hypersensitive nerve fibers, including endometriosis. The hypothesis is that P2X3 receptor antagonism can inhibit cycles of pain causing neurogenic inflammation, causing pain, etc. modifying the underlying disease in [...]



Other molecules you may be interested in